176 related articles for article (PubMed ID: 2702423)
1. Intravesical Evans Bacille Calmette-Guérin in the treatment of carcinoma in situ.
Cumming JA; Hargreave TB; Webb JN; McIntyre MA; Chisholm GD
Br J Urol; 1989 Mar; 63(3):259-63. PubMed ID: 2702423
[TBL] [Abstract][Full Text] [Related]
2. Intravesical Evans bacille Calmette-Guérin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group.
Talic RF; Hargreave TB; Bishop MC; Kirk D; Prescott S
Br J Urol; 1994 Jun; 73(6):645-8. PubMed ID: 8032831
[TBL] [Abstract][Full Text] [Related]
3. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
4. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
5. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
6. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
7. Evolution of carcinoma in situ under intravesical Romanian Bacille Calmette-Guérin therapy.
Geavlete P; Taşcă C
Rom J Morphol Embryol; 1991; 37(1-2):69-74. PubMed ID: 1801982
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder.
Ovesen H; Poulsen AL; Steven K
Br J Urol; 1993 Nov; 72(5 Pt 2):744-8. PubMed ID: 8281407
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
10. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
[No Abstract] [Full Text] [Related]
12. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
13. The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer.
Bowyer L; Hall RR; Reading J; Marsh MM
Br J Urol; 1995 Feb; 75(2):188-92. PubMed ID: 7850324
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
[TBL] [Abstract][Full Text] [Related]
15. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
Jakse G
Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Bacillus Calmette Guerin therapy in patients with superficial bladder tumor.
Steg A; Belas M; Leleu C; Boccon-Gibod L
Prog Clin Biol Res; 1989; 303():375-81. PubMed ID: 2780654
[No Abstract] [Full Text] [Related]
17. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.
De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D
Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
19. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
